← Leaderboards

Jeffrey S Weber

University Of Southern California

Google Scholar ↗PubMed ↗ORCID ↗

$20,866,039

Attributed

$23,615,846

Total exposure

21

Grants

10

Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $3.9M · FY2005–25

$5M$3.8M$2.5M$1.3M$0

'05

'06

'07

'08

'09

'10

'11

'12

'13

'14

'15

'16

'17

'18

'19

'20

'21

'22

'23

'24

'25

Funding mix

By agency

NIH$38,853,795 · 22

FDA$600,000 · 1

By mechanism

R01$20,141,418 · 11

P50$17,071,022 · 3

P30$839,047 · 3

R21$663,164 · 1

M01$375,965 · 3

K24$309,719 · 1

Top collaborators

Iman Osman12 shared
Tomas Kirchhoff5 shared
Erik Sulman1 shared

Most similar at University Of Southern California

Same institution · by research overlap

Caryn Lerman$95,133,528
W Martin Kast$9,478,408
Don J Diamond$24,317,616

Others in their field

Top investigators on “Melanoma”

David Heimbrook · Leidos Biomedical Research, Inc.$206,517,726
Richard L Schilsky · University Of Chicago$108,377,382
Larry Arthur$59,113,709
Charles A Coltman · Southwest Oncology Group$55,198,633
Robert L Comis · Frontier Sci &Technology Rsch Fdn, Inc$47,956,689
Meenhard Herlyn · University Of Pennsylvania$46,448,742

Research focus

MelanomaImmuneBaseClinical TrialsTumorBiological MarkersResponseToxic EffectT-LymphocyteMalignant NeoplasmsClinical ResearchHuman SubjectNeoplasm /Cancer VaccineMetastatic MelanomaImmunotherapyAntibodiesHuman Therapy EvaluationVaccine DevelopmentProgramsCd8b1 GeneInstitutionPredictive MarkerResearch PersonnelResected

Grant awards (89)

NYU Melanoma SPORE$1,230,080

P50 · FY2025 · CA

NYU Melanoma SPORE$896,274

P50 · FY2024 · CA

NYU Melanoma SPORE$2,084,236

P50 · FY2023 · CA

Correlative biomarkers of IL-6 blockade combined with checkpoint inhibition$581,524

R01 · FY2023 · CA · contact PI

K12 Training for Clinical and Translational Oncology Researchers$53,460

K12 · FY2023 · CA · contact PI

NYU Melanoma SPORE$2,035,150

P50 · FY2022 · CA

Correlative biomarkers of IL-6 blockade combined with checkpoint inhibition$581,524

R01 · FY2022 · CA · contact PI

(8) Genomic determinants of the T-cell regulome in immune checkpoint blockade$510,554

R01 · FY2022 · CA

(PQ8) Predicting immune-related toxicity in the adjuvant melanoma setting with checkpoint inhibition$360,682

R01 · FY2022 · CA

NYU Melanoma SPORE$2,065,182

P50 · FY2021 · CA

(8) Genomic determinants of the T-cell regulome in immune checkpoint blockade$627,894

R01 · FY2021 · CA

Correlative biomarkers of IL-6 blockade combined with checkpoint inhibition$593,391

R01 · FY2021 · CA · contact PI

(PQ8) Predicting immune-related toxicity in the adjuvant melanoma setting with checkpoint inhibition$495,996

R01 · FY2021 · CA

NYU Melanoma SPORE$2,109,068

P50 · FY2020 · CA

(8) Genomic determinants of the T-cell regulome in immune checkpoint blockade$639,149

R01 · FY2020 · CA

Correlative biomarkers of IL-6 blockade combined with checkpoint inhibition$610,766

R01 · FY2020 · CA · contact PI

(PQ8) Predicting immune-related toxicity in the adjuvant melanoma setting with checkpoint inhibition$566,338

R01 · FY2020 · CA

NYU Melanoma SPORE$2,063,466

P50 · FY2019 · CA

(8) Genomic determinants of the T-cell regulome in immune checkpoint blockade$599,504

R01 · FY2019 · CA

(PQ8) Predicting immune-related toxicity in the adjuvant melanoma setting with checkpoint inhibition$543,889

R01 · FY2019 · CA

(8) Genomic determinants of the T-cell regulome in immune checkpoint blockade$620,860

R01 · FY2018 · CA

(PQ8) Predicting immune-related toxicity in the adjuvant melanoma setting with checkpoint inhibition$481,288

R01 · FY2018 · CA

Rational Sequencing of PD-1 and CTLA-4 Antibodies in Metastatic Melanoma$339,297

R01 · FY2017 · CA · contact PI

Administration and Clinical Trials$284,583

P50 · FY2017 · CA · contact PI

Rational Sequencing of PD-1 and CTLA-4 Antibodies in Metastatic Melanoma$339,297

R01 · FY2016 · CA · contact PI

Administration and Clinical Trials$258,116

P50 · FY2016 · CA · contact PI

Rational Sequencing of PD-1 and CTLA-4 Antibodies in Metastatic Melanoma$328,454

R01 · FY2015 · CA · contact PI

Administration and Clinical Trials$273,804

P50 · FY2015 · CA · contact PI

Moffitt Skin Cancer SPORE$1,681,719

P50 · FY2014 · CA · contact PI

Rational Sequencing of PD-1 and CTLA-4 Antibodies in Metastatic Melanoma$318,600

R01 · FY2014 · CA · contact PI

Administration and Clinical Trials$209,543

P50 · FY2014 · CA · contact PI

Moffitt Skin Cancer SPORE$1,672,774

P50 · FY2013 · CA · contact PI

Rational Sequencing of PD-1 and CTLA-4 Antibodies in Metastatic Melanoma$345,579

R01 · FY2013 · CA · contact PI

PD-1 Abrogation and Immunity in Melanoma$298,576

R01 · FY2013 · CA · contact PI

Administration and Clinical Trials$207,027

P50 · FY2013 · CA · contact PI

PD-1 Abrogation and Immunity in Melanoma$317,634

R01 · FY2012 · CA · contact PI

PD-1 abrogation and immunity in melanoma$200,000

R01 · FY2012 · FD · contact PI

PD-1 Abrogation and Immunity in Melanoma$317,634

R01 · FY2011 · CA · contact PI

PD-1 abrogation and immunity in melanoma$78,850

R01 · FY2011 · FD · contact PI

CD40 and TLR Agonists in Melanoma$331,582

R21 · FY2010 · CA · contact PI

PD-1 Abrogation and Immunity in Melanoma$329,064

R01 · FY2010 · CA · contact PI

Protocol Review and Monitoring System: Clinical Investigations & Quality Assuran$195,153

P30 · FY2010 · CA · contact PI

CD40 and TLR Agonists in Melanoma$331,582

R21 · FY2009 · CA · contact PI

PD-1 Abrogation and Immunity in Melanoma$328,315

R01 · FY2009 · CA · contact PI

PD-1 abrogation and immunity in melanoma$321,150

R01 · FY2009 · FD · contact PI

Protocol Review and Monitoring System: Clinical Investigations & Quality Assuran$197,914

P30 · FY2009 · CA · contact PI

Dendritic Cell Vaccination During Lymphoid Reconstitution$603,745

R01 · FY2008 · CA · contact PI

CTLA-4 Inhibition and Autoimmunity in Melanoma$450,477

R01 · FY2008 · CA · contact PI

Protocol Review and Monitoring System: Clinical Investigations & Quality Assuran$169,471

P30 · FY2008 · CA · contact PI

Dendritic Cell Vaccination During Lymphoid Reconstitution$602,707

R01 · FY2007 · CA · contact PI

CTLA-4 Inhibition and Autoimmunity in Melanoma$490,127

R01 · FY2007 · CA · contact PI

Protocol Review and Monitoring System: Clinical Investigations & Quality Assuran$190,557

P30 · FY2007 · CA · contact PI

Dendritic Cell Vaccination During Lymphoid Reconstitution$516,595

R01 · FY2006 · CA · contact PI

CTLA-4 Inhibition and Autoimmunity in Melanoma$486,496

R01 · FY2006 · CA · contact PI

Protocol Review and Monitoring System: Clinical Investigations & Quality Assuran$85,952

P30 · FY2006 · CA · contact PI

Dendritic Cell Vaccination During Lymphoid Reconstitution$536,345

R01 · FY2005 · CA

CTLA-4 Inhibition and Autoimmunity in Melanoma$486,967

R01 · FY2005 · CA

CTLA-4 Inhibition and Autoimmunity in Melanoma$506,157

R01 · FY2004 · CA

A Phase I Study of the Toxicities &Biologic Effects$28,884

M01 · FY2004 · RR

HPV DNA VACCINE FOR CERVICAL PRE NEOPLASIA$382,991

R01 · FY2003 · CA

IN VITRO/IN VIVO ACTIVATED DENDRITIC CELLS FOR MELANOMA$357,719

R01 · FY2003 · CA

IL-12 as an Adjuvant for a Melanoma Peptide Vaccine$292,747

R01 · FY2003 · CA

MENTORED PROGRAM IN HUMAN PAPILLOMAVIRUS IMMUNOTHERAPY$79,285

K24 · FY2003 · CA

HPV DNA VACCINE FOR CERVICAL PRE NEOPLASIA$374,898

R01 · FY2002 · CA

IN VITRO/IN VIVO ACTIVATED DENDRITIC CELLS FOR MELANOMA$348,348

R01 · FY2002 · CA

IL-12 as an Adjuvant for a Melanoma Peptide Vaccine$288,671

R01 · FY2002 · CA

MENTORED PROGRAM IN HUMAN PAPILLOMAVIRUS IMMUNOTHERAPY$78,092

K24 · FY2002 · CA

CORE--PROTOCOL SPECIFIC RESEARCH SUPPORT$0

P30 · FY2002 · CA

CORE--PROTOCOL REVIEW AND MONITORING SYSTEM$0

P30 · FY2002 · CA

CORE--PROTOCOL REVIEW AND MONITORING SYSTEM$0

P30 · FY2002 · CA

CEA PEPTIDE PULSED DENDRITIC CELL VACCINE FOR ADVANCE RENAL CELL CANCER$0

M01 · FY2002 · RR

CORE--PROTOCOL SPECIFIC RESEARCH SUPPORT$0

P30 · FY2002 · CA

HPV DNA VACCINE FOR CERVICAL PRE NEOPLASIA$367,170

R01 · FY2001 · CA

IN VITRO/IN VIVO ACTIVATED DENDRITIC CELLS FOR MELANOMA$339,799

R01 · FY2001 · CA

IL12 as an Adjuvant for a Melanoma Peptide Vaccine$293,502

R01 · FY2001 · CA

CEA PEPTIDE PULSED DENDRITIC CELL VACCINE FOR ADVANCE RENAL CELL CANCER$155,764

M01 · FY2001 · RR

MENTORED PROGRAM IN HUMAN PAPILLOMAVIRUS IMMUNOTHERAPY$76,945

K24 · FY2001 · CA

CORE--PROTOCOL SPECIFIC RESEARCH SUPPORT$0

P30 · FY2001 · CA

CORE--PROTOCOL SPECIFIC RESEARCH SUPPORT$0

P30 · FY2001 · CA

CORE--PROTOCOL REVIEW AND MONITORING SYSTEM$0

P30 · FY2001 · CA

CORE--PROTOCOL REVIEW AND MONITORING SYSTEM$0

P30 · FY2001 · CA

CEA PEPTIDE PULSED DENDRITIC CELL VACCINE FOR ADVANCE RENAL CELL CANCER$0

M01 · FY2001 · RR

HPV DNA VACCINE FOR CERVICAL PRE NEOPLASIA$392,172

R01 · FY2000 · CA

IN VITRO/IN VIVO ACTIVATED DENDRITIC CELLS FOR MELANOMA$347,976

R01 · FY2000 · CA

CEA PEPTIDE PULSED DENDRITIC CELL VACCINE FOR ADVANCE RENAL CELL CANCER$155,764

M01 · FY2000 · RR

MENTORED PROGRAM IN HUMAN PAPILLOMAVIRUS IMMUNOTHERAPY$75,397

K24 · FY2000 · CA

CEA PEPTIDE PULSED DENDRITIC CELL VACCINE FOR ADVANCE RENAL CELL CANCER$35,553

M01 · FY2000 · RR

PHASE II STUDY OF DOLASTATIN-10 FOR ADVANCED MELANOMA$0

M01 · FY2000 · RR

PHASE II STUDY OF DOLASTATIN-10 FOR ADVANCED MELANOMA$0

M01 · FY2000 · RR